May 22, 2006 - The purchase price represents a 70% premium on the closing price of CAT's shares on the London Stock Exchange on May 12, the last busin...
GCP Applied Technologies has agreed to buy U.K.-based Stirling Lloyd, a supplier of waterproofing membranes and coatings, for $94 million. Stirling Lloyd has $40 million in annual sales. GCP says the acquisition expands its liquid waterproofing and b
Merck KGaA has acquired Natrix Separations, an Ontario-based producer of hydrogel membrane products for single-use chromatography. Natrix markets both ...
Oct 29, 2018. Vol. 96, Issue 42. Oct 22, 2018. Vol. 96, Issue 41. Oct 15, 2018. Vol. 96, Issue 40. Oct 08, 2018. SEE PAST ISSUES,. 1923 TO PRESENT >.
Rubius Therapeutics, a Cambridge, Mass.-based developer of red-blood-cell-based therapies, has raised $120 million in a financing round that included its founding investor, Flagship Pioneering, as well as other investors. Rubius engineers red blood c
Cyanotech, a biotechnology company based in Woodinville, Wash., "won't be profitable until 1988," says Arthur Karuna-Karan, president of the fledgling ...
based developer of red-blood-cell-based therapies, has raised $120 million in a financing round that included its founding investor, Flagship Pioneering, as well as other investors. Rubius engineers red blood cells to express enzymes, agonists, antag
Seeking to become a leader in treating blood disorders, Bioverativ will pay $400 million up front to acquire privately held True North Therapeutics. Bioverativ, a Biogen spin-off, adds to its portfolio TNT009, a monoclonal antibody in early-stage stu
Monsanto will buy the plant biotechnology assets of W.R. Grace's Agracetus ... The technology has helped create transgenic versions of cotton, soybeans, beans, and .... CRISPR/Cas9 gene-editing system was invented just over six years.
Japan's Sosei Group will spend $45 million to acquire a 25.6% ownership stake in MiNA Therapeutics and an option to potentially acquire all of the London-based firm. MiNA's lead compound is MTL-CEBPA, a small activating RNA that is in the midst of Ph
JSR has agreed to acquire Selexis, a Swiss firm with a mammalian cell-line generation technology said to improve yields of protein therapies such as bispecific antibodies, multimeric proteins, and Fc-fusion proteins. Low yields, weak protein expressi
